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Abstract
Aims/hypothesis The aim of the study was to compare the
efficacy and safety of liraglutide in type 2 diabetes mellitus
vs placebo and insulin glargine (A21Gly,B31Arg,B32Arg
human insulin), all in combination with metformin and
glimepiride.
Methods This randomised (using a telephone or web-based
randomisation system), parallel-group, controlled 26 week
trial of 581 patients with type 2 diabetes mellitus on prior
monotherapy (HbA1c 7.5–10%) and combination therapy
(7.0–10%) was conducted in 107 centres in 17 countries.
The primary endpoint was HbA1c. Patients were randomised
(2:1:2) to liraglutide 1.8 mg once daily (n=232), liraglutide
placebo (n=115) and open-label insulin glargine (n=234), all
in combination with metformin (1 g twice daily) and
glimepiride (4 mg once daily). Investigators, participants
and study monitors were blinded to the treatment status of
the liraglutide and placebo groups at all times.
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DOI 10.1007/s00125-009-1472-yResults The number of patients analysed as intention to treat
were: liraglutide n=230, placebo n=114, insulin glargine n=
232. Liraglutide reduced HbA1c significantly vs glargine
(1.33% vs 1.09%; −0.24% difference, 95% CI 0.08, 0.39; p=
0.0015) and placebo (−1.09% difference, 95% CI 0.90, 1.28;
p<0.0001). There was greater weight loss with liraglutide
vs placebo (treatment difference –1.39 kg, 95% CI 2.10,
0.69; p=0.0001), and vs glargine (treatment difference
−3.43 kg, 95% CI 4.00, 2.86; p<0.0001). Liraglutide reduced
systolic BP (−4.0 mmHg) vs glargine (+0.5 mmHg;
−4.5 mmHg difference, 95% CI 6.8, −2.2; p=0.0001) but
not vs placebo (p=0.0791). Ratesofhypoglycaemicepisodes
(major, minor and symptoms only, respectively) were 0.06,
1.2 and 1.0 events/patient/year, respectively, in the liraglutide
group (vs 0, 1.3, 1.8 and 0, 1.0, 0.5 with glargine and placebo,
respectively). A slightly higher number of adverse events
(including nausea at 14%) were reported with liraglutide, but
only 9.8% of participants in the group receiving liraglutide
developed anti-liraglutide antibodies.
Conclusions/interpretation Liraglutide added to metformin
and sulfonylurea produced significant improvement in
glycaemic control and bodyweight compared with
placebo and insulin glargine. The difference vs insulin
glargine in HbA1c was within the predefined non-inferiority
margin.
Trial registration: ClinicalTrials.gov NCT00331851
Funding: The study was funded by Novo Nordisk A/S.
Keywords DPP-4.Exenatide.Incretin.Insulinglargine.
LEAD-5
Abbreviations
AACE American Association of Clinical
Endocrinologists
ACE American College of Endocrinology
ADA American Diabetes Association
AEs Adverse events
ANCOVA Analysis of covariance
DPP-4 Dipeptidyl peptidase 4
GLP-1 Glucagon-like peptide-1
GSRS Gastrointestinal Symptoms Rating Scale
LDL-C Low density lipoprotein-cholesterol
NGSP National Glycohemoglobin Standardization
Program
OGLA Oral glucose-lowering drug
PG Plasma glucose
PPG Postprandial plasma glucose
TTT Treat to target
VAS Visual analogue scale
Introduction
Type 2 diabetes mellitus is a progressive multi-system
disease in which individuals exhibit varying degrees of
declining beta cell function, insulin resistance and a
failure to suppress postprandial glucagon secretion. It is
associated with an array of co-morbidities and potentially
devastating complications. Currently available therapies
do not adequately control glycaemia in the long term as
they do not address the issue of declining beta cell
function and do not impact positively on weight or
cardiovascular concerns associated with the disease.
Furthermore, such therapies often comprise complex
treatment and titration regimens and can increase the
risk of hypoglycaemia and undesirable effects such as
oedema and weight gain [1].
Glucagon-like peptide-1 (GLP-1) is a naturally occurring
incretin hormone with a wide range of physiological actions
that make it a potent blood-glucose-lowering agent with the
potential to modify the natural history of type 2 diabetes
[2]. In animal models, native GLP-1 stimulates beta cell
proliferation, inhibits apoptosis in vitro (which may
increase beta cell mass and function) and may have a
number of cardiovascular and other benefits [3]. The
glucose-lowering actions of GLP-1 are glucose dependent,
which limits the risk of hypoglycaemia [4]. However, its
very short half-life, consequent to its rapid metabolism by
the enzyme dipeptidyl peptidase-4 (DPP-4), limits its
therapeutic potential [2].
Liraglutide is a once-daily human GLP-1 analogue
with a high degree (97%) of amino-acid-sequence
identity with native human GLP-1 [5]. The molecule
has a half-life of 13 h making it suitable for once-daily
subcutaneous administration [6–8]. Clinical data from
early clinical trials demonstrate that liraglutide reduces
blood glucose, bodyweight and systolic blood pressure
(SBP) [9].
The objective of the present study was to compare the
efficacy and safety of liraglutide with that of self-titrated
basal insulin glargine (A21Gly,B31Arg,B32Arg human
insulin) in patients with type 2 diabetes not adequately
controlled with metformin and glimepiride.
Methods
Design overview
This 26 week randomised, parallel-group, placebo-controlled
study (with liraglutide placebo and open-label insulin
glargine arms) was carried out in adult patients with type 2
diabetes.
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The 581 randomised patients in this multicentre (107 sites),
multinational (17 countries) trial were 18–80 years old,
with type 2 diabetes treated with oral glucose-lowering
drugs (OGLAs) (94–95% combination therapy) (Table 1)
for at least 3 months before screening. General inclusion
criteria included: HbA1c level of 7.5–10% if on OGLA
monotherapy or 7–10% if on OGLA combination therapy,
and BMI≤45kg/m
2. Patients were excluded if they: had
used insulin within 3 months prior to the trial (except for
short-term treatment for intercurrent illness); had impaired
hepatic or renal function, clinically significant cardiovas-
cular disease, proliferative retinopathy or maculopathy,
hypertension (≥180/100 mmHg) or cancer; were pregnant;
experienced recurrent hypoglycaemia or hypoglycaemia
unawareness; were seropositive for hepatitis B antigen or
hepatitis C antibody; or used any drugs except for OGLAs
that could affect blood glucose levels. The trial was
conducted in accordance with the Declaration of Helsinki
and ICH Good Clinical Practice. Written informed consent
was obtained from patients prior to commencement of the
trial, and protocols and consent forms were approved by the
local health authorities, the local independent ethics
committees and institutional review boards (Electronic
supplementary material [ESM]).
Randomisation and interventions
Randomisation (using a telephone or web-based random-
isation system) followed a 6 week run-in period during
which participants were placed on a standard combination
therapy with metformin and glimepiride: forced metformin
and glimepiride dose escalation over 3 weeks followed by a
3 week maintenance period. Participants already on 2 g
metformin and sulfonylurea therapy could proceed directly
to the maintenance regimen at the discretion of the
investigator. During the dose-escalation period, doses of
metformin and glimepiride were increased by up to 2 g/day
and 4 mg/day, respectively.
Patients were randomised if they met the inclusion
criteria, had received glimepiride (4 mg) and metformin
(2 g) treatment for at least 3 weeks and had a fasting plasma
glucose (FPG) between 7.5 and 12.8 mmol/l after the
6 week run-in. All patients were stratified at randomisation
based on their previous therapy (OGLA monotherapy or
combination therapy).
Patients were randomly allocated to three interventions
(2:1:2) to receive: once-daily liraglutide (blinded); once-
daily liraglutide placebo (blinded) or once-daily insulin
glargine (open-labelled; sanofi-aventis, Paris, France), all in
combination with metformin and glimepiride (open-la-
belled). Liraglutide and liraglutide placebo were supplied
by Novo Nordisk A/S (Bagsvaerd, Denmark). Investigators,
participantsandstudymonitorswereblindedtothetreatment
status of the liraglutide and placebo groups at all times.
Dosing
The 1.8 mg liraglutide dose selected for this study was
based on previously completed phase 2 dose-range-finding
studies [9]. After randomisation, patients in the liraglutide
group underwent a 2 week dose escalation, starting at
0.6 mg once daily with weekly increments of 0.6 mg,
reaching a final daily dose of 1.8 mg by the end of the
second week; daily placebo injections were matched for
volume. After the 2 week dose-escalation period the
liraglutide dose was fixed for 24 weeks. Trial medication
was administered by subcutaneous injection in the abdo-
men, thigh or upper arm using a pre-filled pen device (with
Table 1 Patient baseline characteristics
Characteristic Liraglutide Placebo Insulin glargine p value*
Male/female (%) 57:43 49:51 60:40 0.142
Age (years) 57.6 (9.5) 57.5 (9.6) 57.5 (10.5) 0.968
Duration of diabetes (years) 9.2 (5.8) 9.4 (6.2) 9.7 (6.4) 0.773
Previously on monotherapy:combination therapy at screening (%) 6:94 5:95 5:95 0.802
Fasting plasma glucose (mmol/l) 9.1 (2.1) 9.4 (2.0) 9.1 (2.0) 0.444
HbA1c (%) 8.3 (0.9) 8.3 (0.9) 8.2 (0.9) 0.293
Body mass index (kg/m
2) 30.4 (5.3) 31.3 (5.0) 30.3 (5.3) 0.290
Weight (kg) 85.5 (19.4) 85.7 (16.7) 85.0 (17.9) 0.999
Systolic blood pressure (mmHg) 135 (15.0) 133 (14.0) 133 (14.7) 0.244
Diastolic blood pressure (mmHg) 80.8 (9.1) 80.4 (9.3) 80.5 (8.0) 0.962
Values are mean (SD)
*p>0.05 indicates no significant difference between the three treatments
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injection could be administered at any time of the day.
Participants were encouraged to inject liraglutide during the
same overall time period on a day-to-day basis.
Reduction of glimepiride dose from 4 mg to 2 mg was
allowed after randomisation if necessitated by adverse
events (AEs) or hypoglycaemia.
As in similar previous studies [10, 11], insulin glargine
(100 IU/ml injected once daily with OptiSet; sanofi-aventis)
was titrated by patients following instruction by the investi-
gator according to a specific and widely adopted dosing
algorithm for insulin glargine based on fasting concentration
of blood glucose (adapted from A Trial comparing Lantus
Algorithms to achieve Normal blood glucose Targets in
patients with Uncontrolled blood Sugar [AT-LANTUS])
[11]. The starting dose of insulin glargine was numerically
equivalent to the highest FPG value in mmol/l over the
previous 7 days (e.g. if the FPG measure was 10 mmol/l, the
initial glargine dose would be 10 IU). This facilitated ease of
initiation in this patient-driven titration. During the first
8 weeks of treatment, the dose was titrated twice weekly by
the participant, based on self-measured FPG, aiming for a
target value of FPG≤5.5 mmol/l. After 8 weeks of treatment,
the frequency of monitoring and titration was at the
investigator’s discretion, but at minimum the insulin glargine
dose was adjusted at the 12 and 18 week visits. The
investigator reviewed the doses and these could be changed
at his/her discretion. The injection could be administered at
any time of the day, but the selected time of the day
remained the same throughout the trial.
Treatment allocation
Participants eligible for randomisation were assigned to
liraglutide, liraglutide placebo or insulin glargine in a
2:1:2 randomisation pattern. At screening, all partic-
ipants were given a 6 digit participant number. At
randomisation, eligible participants were allocated to
one of the three treatment groups using a telephone- or
web-based randomisation system. Participants were strat-
ified by whether they were treated with monotherapy or
combination therapy for their diabetes at screening. A
block size of five was defined for both groups. The
blinded electronic-sealed codes were accessible to the
investigators, affiliate and international product safety
personnel or any other relevant party who might have
had a need for breaking the treatment code; for example,
for safety or regulatory purposes. Break of the code was
performed through the telephone- or web-based random-
isation system via an emergency code-break call. Novo
Nordisk trial personnel, international product safety
personnel, and the investigator received a notification
generated by the interactive voice response system/
interactive web response system via an emergency
code-break call.
Outcomes and follow-up
The primary efficacy outcome measure was change in
whole blood HbA1c after 26 weeks of treatment. The
secondary outcome measures included changes in body-
weight, waist circumference, FPG, eight point plasma
glucose (PG) profiles, beta cell function (proinsulin to
C-peptide ratio) and BP.
HbA1c was measured (at baseline and at weeks 12, 18 and
26) using high-performance liquid chromatography according
to an assay certified by the National Glycohemoglobin
Standardization Program (NGSP). Self-measurement of PG
from capillary samples was performed using a Medisense
Precision Xtra/MediSense Optimum glucose meter (Abbott,
Maidenhead, UK) that used test strips calibrated to plasma
values. Insulin and C-peptide were measured in serum using a
chemiluminescence immunoassay. Proinsulin was measured
in serum using an enzyme-linked immunosorbent assay.
Glucagon was measured by RIA in aprotinin-treated plasma.
Safety assessments included hypoglycaemic episodes
based on symptoms and PG (<3.1 mmol/l). Episodes
requiring third-party medical assistance were classified as
major. Liraglutide antibodies were measured by radio-
precipitation assay using
125I-labelled liraglutide tracer
and polyethylene glycol precipitation. Vital signs, ECG,
calcitonin and biochemical and haematology measures were
recorded. All AEs, either observed by the investigator or
reported spontaneously by the participants, were recorded
by the investigator. The participants were asked at each
post-screening visit or contact with the site if they had had
any AEs (including changes in concomitant illness or new
illnesses) since the last evaluation. The participant was
asked: ‘Have you experienced any problems since the last
contact?’
The trial comprised a 2 week screening period followed
by a 3 week dose-escalation period, a 3 week maintenance
period and then a 26 week treatment period. The follow-up
period was 1 week. In total the participants attended
nine visits at the site and had two telephone contacts
(week 1 and 4 post-randomisation) during the trial
duration of a maximum of 36 weeks. At screening, the
participants were assigned a unique participant number.
Inclusion and exclusion criteria were reviewed prior to
randomisation. The randomisation criteria were reviewed
at the randomisation visit. At each visit, information
was collected and/or procedures performed according to
the protocol. Patients recorded information in diaries
between the visits to be reviewed at each visit. Week 26
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a follow-up visit (week 27). Participants with a confirmed
FPG reading >13.3 mmol/l at week 8 or thereafter and no
intercurrent treatable illness were withdrawn from the
study.
Statistical analyses
The data were analysed for the intent-to-treat population,
defined as patients who were exposed to at least one dose
of trial product(s) after randomisation. For the primary
endpoint, HbA1c, the statistical analysis was also performed
without the last observation carried forward on the per-
protocol population (participants completing the study
without significant protocol violations) (ESM Table 1).
Each endpoint was analysed using an analysis of covariance
(ANCOVA) model with treatment, pre-treatment and
country as fixed effects and baseline as the covariate.
Missing baseline values were not imputed; that is, partic-
ipants without a baseline value were excluded from the
primary analysis. Post-baseline missing values were
replaced using last observation carried forward. Sample
size calculations were based on predicted HbA1c and
bodyweight after 26 weeks of treatment.
The study was powered against the primary endpoint
change in HbA1c. The non-inferiority margin against
glargine was set to 0.4% and the difference to detect
superiority against placebo was set to 0.5%. In addition the
study was powered to detect a 3% difference in weight. The
combined power was greater than 85%.
For superiority and non-inferiority of liraglutide vs
comparators, hierarchical tests were conducted. The prima-
ry endpoint was the change from baseline in HbA1c after
26 weeks of treatment. A sequential testing procedure was
employed to protect the overall type 1 error rate. First,
superiority of liraglutide to that of placebo had to be declared,
then non-inferiority against glargine was tested and, if
declared, superiority was tested. Finally, a test for superiority
of insulin glargine vs placebo was performed.
The proportion of participants achieving HbA1c targets
(American Diabetes Association [ADA] target: <7% [12];
American Association of Clinical Endocrinologists [AACE]
target ≤6.5% [13]) was compared between treatments using
a logistic regression model with treatment as fixed effect
and baseline HbA1c as a covariate. Hypoglycaemic epi-
sodes were analysed using a generalised linear model
including treatment and country as fixed effects. Other
safety data were compared by descriptive statistics. Values
are expressed as means ± SD unless otherwise noted;
significance was set at p<0.05. For the primary analysis
(non-inferiority/superiority) the level of significance was
2.5% (one-sided test) and 5% (two-sided test).
Results
Demographics and disposition
A total of 973 patients were screened, 581 were randomised
and 522 completed the study (Fig. 1). The highest
withdrawal rate was seen in the placebo group, which was
mainly driven by withdrawal because of ineffective therapy
at a level of 11.3%. AE withdrawals occurred for 4.7%
(liraglutide), 0.9% (placebo) and 2.1% (insulin glargine) of
participants. Treatment groups were well matched (Table 1).
The average dose of insulin glargine was 24 IU/day at the
end-of-trial visit, giving 20% and 40% of the group
reaching an FPG≤5.5 and <6.7 mmol/l, respectively. The
average daily doses of glimepiride at the end of the study
were 3.4 mg in the liraglutide group, 3.9 mg in the placebo
group and 3.6 mg in the insulin glargine group.
Efficacy
HbA1c After 26 weeks of treatment, the HbA1c reduction
from baseline with liraglutide was 1.33% (SEM 0.09) (final
mean HbA1c 7.0%), with placebo 0.24% (SEM 0.11) (final
mean HbA1c 8.1%) and with insulin glargine 1.09% (0.09
SEM) (final mean HbA1c 7.2%) (Fig. 2). The lowest HbA1c
level was observed at 12 and 18 weeks for liraglutide and
insulin glargine, respectively. Thereafter both groups had a
minor increase towards week 26. The reduction in HbA1c
with liraglutide was significantly greater than the reductions
observed in both the placebo and insulin glargine groups
(treatment differences for liraglutide vs placebo −1.09%,
95% CI −1.28, −0.90; p<0.0001 and liraglutide vs insulin
glargine −0.24%, 95% CI −0.39, −0.08; p=0.0015). The
HbA1c reduction in the insulin glargine group was also
significantly greater than in the placebo group (treatment
difference −0.85%, 95% CI −1.04, −0.66; p<0.0001).
Similar results for HbA1c were achieved using the per-
protocol analysis population (data not shown).
Significantly more patients reached HbA1c AACE
targets of ≤6.5% [13] and ADA targets of <7% [12] with
liraglutide than with either placebo or insulin glargine
(ESM Fig. 1).
Bodyweight The mean weight loss from baseline of 1.8 kg
(SEM 0.33) achieved in the liraglutide group was signifi-
cantly superior to the reduction in the placebo group
(0.42 kg [SEM 0.39]; weight difference of −1.39 kg, 95%
CI −2.10, −0.69; p=0.0001) (Fig. 3). Weight increased by
1.6 kg (SEM 0.33) with insulin glargine, resulting in a
mean treatment difference of −3.43 kg (95% CI −4.00,
−2.86; p<0.0001) (Fig. 3). In addition, the reduction in
waist circumference for the liraglutide group (1.50 cm) was
2050 Diabetologia (2009) 52:2046–2055statistically significant compared with the insulin glargine
group (0.89 cm increase; treatment difference −2.40 cm,
95% CI −3.14, −1.65; p<0.0001), but not compared with
the placebo group (0.62 cm reduction; treatment difference
−0.88 cm, 95% CI −1.81, 0.04; p=0.0608).
Overall, weight loss was independent of nausea, although
in the very small number of patients (n=8) with sustained
nausea, there seemed to be a greater weight loss (−3.2 kg).
FPG FPG decreased rapidly with liraglutide (ESM Fig. 2);
final reductions in FPG from baseline were 1.55 mmol/l for
liraglutide and 1.79 mmol/l for insulin glargine, with an
increase of 0.53 mmol/l for placebo. The reduction in mean
FPG in the liraglutide group, and the likelihood of
achieving ADA targets (FPG 5–7.2 mmol/l) was signifi-
cantly superior compared with the placebo group (treatment
difference for FPG −2.08 mmol/l [95% CI 2.53, −1.64], p<
0.0001 and odds ratio 4.99, 95% CI 2.65–9.39) but not vs
the insulin glargine group.
Postprandial plasma glucose A reduction in postprandial
plasma glucose (PPG) from baseline was observed in the
liraglutide (1.81 mmol/l) and insulin glargine (1.61 mmol/l)
groups, with the reduction with liraglutide being significantly
greater than with placebo (0.03 mmol/l; treatment difference
−1.84 mmol/l, 95% CI −2.36, −1.33; p<0.0001) but not vs
0246
9.0
8.0
7.0
6.0
5.0
0
81 0 1 2
Time (weeks)
H
b
A
1
c
 
(
%
)
14 16 18 20 22 24 26
*
Fig. 2 HbA1c (%) over time (last observation carried forward,
intention-to-treat population). Liraglutide 1.8 mg (squares); glargine
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Fig. 1 Flow of patients through the study
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likelihood of achieving ADA targets for PPG (≤10 mmol/l)
(p<0.0001) with liraglutide vs placebo.
Beta cell function The proinsulin to C-peptide ratio showed
a significant improvement in the liraglutide group com-
pared with the insulin glargine group (treatment difference
−0.00366, 95% CI −0.00597, −0.00136; p=0.0019) and the
placebo group (treatment difference −0.00671, 95% CI
−0.00964, −0.00377; p<0.0001).
Cardiovascular effects A significant reduction in SBP was
observed with liraglutide (4.0 mmHg reduction) compared
with insulin glargine (0.54 mmHg increase; treatment
difference −4.51 mmHg, 95% CI −6.82, −2.20; p=0.0001),
but not in comparison with placebo (1.4 mmHg reduction;
treatment difference −2.53 mmHg, 95% CI −5.36, 0.29;
p=0.0791). No significant difference in the reduction in
diastolic BP was observed relative to either comparator.
Based on the time course of SBP and weight reductions, the
reduction in SBP occurred before substantial weight loss.
The pulse rate increased by an estimated mean 2.62 beats/
min in the liraglutide group, 0.08 beats/min in the glargine
group (treatment difference 2.54 beats/min; 95% CI 1.10, 3.98;
p=0.0006) and 0.93 beats/min in the placebo group (treatment
difference 1.70 beats/min; 95% CI −0.06, 3.45; p=0.0582).
Safety
Hypoglycaemic episodes The proportion of patients ex-
periencing minor hypoglycaemia (FPG <3.1 mmol/l) during
the treatment period in the liraglutide group (27.4% patients)
was not different from the insulin glargine group (28.9%) but
higher compared with the placebo group (16.7%). The rate of
hypoglycaemic episodes (major, minor and symptoms only,
respectively) was 0.06, 1.2 and 1.0 events/patient/year in the
liraglutide group; 0, 1.3 and 1.8 events/patient/year in the
glargine group; and 0, 1.0 and 0.5 events/patient/year in
the placebo group.
Five patients reported major hypoglycaemic events in
the liraglutide group (2.2%; only one required medical
assistance and none resulted in coma or seizures). None of
these was nocturnal. No major events were reported in the
glargine group or in the placebo group.
Adverse events The most common AEs in the liraglutide
group were gastrointestinal and of mild or moderate
severity (mainly nausea) (Table 2). Altogether, four patients
withdrew within 2 weeks with a gastrointestinal AE.
Nausea occurred in 14% of patients in the liraglutide
group, decreasing after 1–3 weeks of treatment and reach-
ing a stable level (1.5%) after 14 weeks; diarrhoea occurred
in 10% of patients and vomiting in 7%.
Although AEs were reported more frequently for the
liraglutide group, serious AEs were reported less frequently in
the liraglutide group (4%) than in the placebo (7%) and insulin
glargine groups (7%). No case of pancreatitis was reported. A
summary of AEs has been provided as ESM Table 2.
After 26 weeks there was a comparable and significant
increase in calcitonin levels for both liraglutide and insulin
glargine vs placebo. The estimated mean calcitonin level at
26 weeks was within the normal range for participants
treated with both liraglutide and insulin glargine. Anti-
bodies to liraglutide were present in 9.8% of patients in the
liraglutide group. The antibodies did not appear to alter the
glucose-lowering effect of liraglutide.
Discussion
In this study, we found that liraglutide, administered once
daily, was statistically superior to placebo in combination
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carried forward, intention-to-treat population). Liraglutide 1.8 mg
(squares); glargine (diamonds); placebo (triangles). b Change in
bodyweight from baseline (mean [SD]) (last observation carried
forward, intention-to-treat population). *Significant vs glargine (p<
0.0001) and placebo (p=0.0001)
2052 Diabetologia (2009) 52:2046–2055with metformin and glimepiride in patients whose diabetes
was inadequately controlled on these OGLAs. And while a
statistically significant difference vs insulin glargine was
also observed, this is of uncertain clinical relevance.
Patients were more likely to meet ADA and AACE HbA1c
targets with liraglutide compared with insulin glargine. In
addition, beta cell function also improved with liraglutide.
Major hypoglycaemic events were observed in the liraglu-
tide group, and not in the placebo and insulin glargine arms.
The present study is the first study comparing a 24 h-acting
GLP-1 analogue with the basal insulin glargine and
therefore provides information as to treatment choices in
patients requiring further intensification of therapy follow-
ing treatment with metformin and a sulfonylurea.
The HbA1c reduction from baseline with liraglutide in
the present study was in line with that reported by Vilsbøll
and colleagues in a smaller phase 2 study, where reductions
of 1.45 percentage points were achieved from similar
baseline HbA1c levels of 8.1–8.5% [9]. In a study similar
to the ours, Heine and co-workers compared the exendin-
based GLP-1 agonist exenatide and insulin glargine but
found no difference in change in HbA1c between the two
agents (HbA1c reduction of 1.11% with both agents) [10].
Insulin glargine in this study lowered HbA1c by 1.09%
vs baseline. This reduction in HbA1c, and the dose of
insulin used, was comparable with other insulin glargine
titration trials where titration is driven by patients, and not
via intense patient–carer contact schedules [10, 14–17].
Studies such as AT-LANTUS [11] and Glycemic Optimi-
zation with Algorithms and Labs at Point of Care (GOAL
A1c) [18] show that patients can be encouraged to use
higher insulin doses with slightly higher end-of-study
HbA1c levels than were achieved in the present study
(although baseline HbA1c levels were higher). Where more
intensive titration is undertaken and insulin doses have been
pushed higher, studies have achieved somewhat greater
reductions in HbA1c at the expense of concomitantly higher
levels of hypoglycaemia (and weight gain) [14–21].
Nevertheless, the insulin glargine doses in this study are
valid as they were consistent with documented real-life
scenarios and so the data shown actually represent the most
likely clinical expectations. It would, however, be interest-
ing to compare liraglutide and glargine using a treat-to-
target approach in future studies, perhaps standardising
non-pharmacological interventions such as lifestyle and
patient education.
We found no significant difference between fasting and
postprandial control between liraglutide and insulin glar-
gine. The postprandial data are in contrast to data from a
recently conducted study where a flattening of the
postprandial curve in the 5 h period after a standardised
meal was observed [22]. In addition to its effect on
glycaemic control, liraglutide treatment resulted in signif-
icant weight loss compared with placebo (−1.4 kg differ-
ence) and a favourable weight difference compared with
insulin glargine (−3.4 kg). This is consistent with previous
liraglutide studies [9] where the weight loss vs placebo was
in a similar range.
As with previous liraglutide studies [23], a reduction in
SBP was observed vs insulin glargine, but not in compar-
ison with placebo. Based on the time course of SBP and
weight reductions, the reduction in SBP occurred before
substantial weight loss occurred. The mechanism underly-
ing the reduction in SBP observed in patients with type 2
diabetes treated with liraglutide is unknown, but it has been
demonstrated that infusion of native GLP-1 increases
natriuresis in humans [24]. The long-term safety of
liraglutide and its impact on micro- and cardiovascular
outcomes are yet to be established (as is also the case for
metformin and sulfonylurea).
Although gastrointestinal AEs were reported more
frequently for the liraglutide group, they were mainly mild
to moderate and transient. This is in line with a study where
patient self-assessments of gastrointestinal side effects with
liraglutide were mainly reported in the first weeks after
initiation [25]. In particular, the withdrawal rate in the
present study was low and only very few cases included
gastrointestinal side effects. In addition, the superior
efficacy and positive impact of liraglutide on weight and
weight concern have been associated with clinically
important improvements in physical and emotional domains
of quality of life regardless of AEs [26].
Adverse event Liraglutide Placebo Insulin glargine p value*
n % En% En% E
Nausea 32 13.9 41 4 3.5 4 3 1.3 3 <0.0001
Diarrhoea 23 10.0 29 6 5.3 7 3 1.3 6 <0.0001
Dyspepsia 15 6.5 16 1 0.9 1 4 1.7 4 0.0042
Vomiting 15 6.5 18 4 3.5 4 1 0.4 1 0.0005
Nasopharyngitis 21 9.1 23 10 8.8 10 26 11.2 32 0.6864
Headache 22 9.6 33 9 7.9 14 13 5.6 18 0.2687
Table 2 Individual adverse
events with frequency >5%
*p>0.05 indicates no significant
difference between the three
treatments
E, number of events; n, number
of patients experiencing the AE;
%, percentage experiencing ad-
verse event
Diabetologia (2009) 52:2046–2055 2053Overall rates of hypoglycaemia were higher in the
liraglutide group as compared with the placebo group, but
not different from the insulin glargine group. Five partic-
ipants treated with liraglutide reported six major hypogly-
caemic events. The combination of a sulfonylurea with a
GLP-1 analogue increases the risk of hypoglycaemia, as
has also been reported with exenatide [10, 27, 28]. As also
observed in the present study, an increased risk of major
hypoglycaemic events has been seen in studies where
liraglutide has been combined with a sulfonylurea [29]. The
mechanism behind this may reflect an uncoupling of the
glucose-dependent insulin secretion of GLP-1 when com-
bined with a sulfonylurea [30]. A low frequency of
participants with liraglutide antibodies was observed; these
antibodies did not appear to reduce the efficacy of
liraglutide.
There are certain limitations of this trial that need to be
considered. These include the open-label design of the
insulin glargine arm, the relatively short duration of
treatment assessed and the need for titration of insulin
glargine dose in the third study arm (although proven
titration algorithms were followed). Furthermore, the study
participants had not previously been treated with insulin.
In conclusion, this 26 week trial demonstrated that the
once-daily human GLP-1 analogue liraglutide added to
combination therapy with metformin and glimepiride in
patients with type 2 diabetes resulted in statistically
significant superior glycaemic control compared with
insulin glargine, but the difference was within the prede-
fined non-inferiority margin of 0.4 percentage points.
Liraglutide resulted in weight loss, in contrast with placebo
and with insulin glargine, which caused weight gain. Major
hypoglycaemic events were reported in five participants
treated with liraglutide.
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